Genomic Health
-
Trial results add to uses for Exact Sciences test
The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy — and those who won’t. The latest trial results extend the test’s reach.
-
Diagnostics, Health Services, Health Tech
Exact Sciences buys fellow oncology diagnostics company Genomic Health for $2.8B
The companies tout the deal as expanding Exact’s commercial footprint to 90 countries and creating a leader in the cancer diagnostic space with projected 2020 revenues of $1.6 billion.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Epic Sciences raises $52M Series E round to advance liquid biopsy diagnostics
The San Diego-based firm plans to integrate its “No Cell Left Behind” platform with electronic medical records and big data analytics.
-
Biopharma just can’t get enough of Epic Sciences
Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round and a whopping 42 industry partnerships built around its novel liquid biopsy platform. For a team of just 70, the San Diego startup is doing pretty well.
-
Schering-Plough launches schizophrenia, bi-polar disorder drug after buying maker
Sometimes acquiring other drugmakers is the way to fill your company’s development pipeline with new drugs. On Tuesday, Schering-Plough Corp. CEO Fred Hassan, a speaker at the Cleveland Clinic’s ongoing Medical Innovation Summit, flew to Texas to launch Saphris, an anti-psychotic drug acquired in 2007.